the available evidence suggests, should have expanded with the growth of the NIH itself.
The administration of US President Barack Obama needs to get a grip on this before an explosive high-profile case -such as that of Andrew Wakefield and MMR vaccines in the United Kingdom -turns up and the ORI can't cope. If the administration doesn't do this, Congress just might. Senator Chuck Grassley (Republican, Iowa) demanded in February that the ORI explain its lenient treatment of Dong-Pyou Han, a physician at Iowa State University in Ames, who was banned from seeking NIH funding for three years after falsifying data in AIDS vaccine trials that cost the agency US$19 million.
It is not known how much Grassley's strident demand for answers contributed to Wright's departure. But attention from one of the most feared and respected voices on Capitol Hill can only intensify the political hot-house atmosphere that his resignation letter blames for the ORI's troubles. These troubles go back a long way. The ORI sits under the assistant health secretary, instead of being properly independent like the inspector generals who keep an eye (imperfectly) on scientific fraud at the National Science Foundation (NSF) and other agencies. Its enforcement remit (of fabrication, falsification and plagiarism, or FFP) is too narrow, and its budget too small.
Canada has already shown the way. In 2011, it set up the Tri-Agency Framework: Responsible Conduct of Research. It has a relatively large staff of eight, for a research system one-tenth the size of that of the United States, a remit that reaches far beyond FFP, and it is led by Susan Zimmerman, a tough lawyer unlikely to put up with dodgy academics whimpering about their "creativity".
Wright's resignation comes as a panel chaired by Robert Nerem, a bioengineer at the Georgia Institute of Technology in Atlanta, is in the final stages of the first National Academy of Sciences study on research integrity in 20 years. The report may recommend beefing up the ORI, broadening its remit beyond FFP and aligning its approach with that of the NSF and other agencies. But with the ORI leaderless, the academy report may be even more prone than usual to gathering dust.
I have been an optimist on misconduct: some 18 months ago, I wrote that the global community was starting to get a handle on it. Wright's appointment was progress, and his departure is a setback. His position must be filled promptly by someone respected by both ethicists and health researchers. They will also need the skills to build bridges with Congress: a peripatetic master, perhaps, but one who can prevent the ORI from getting kicked around. ■ Colin Macilwain writes on science policy from Edinburgh, UK. e-mail: cfmworldview@gmail.com
